Juliana Célia Farias dos Santos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Juliana Célia Farias dos Santos has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Fabiana Andréa Moura
College of Nutrition, Federal University of Alagoas, Maceió 57072-970, Alagoas, Brazil
2 shared publications - Kívia Queiroz de Andrade
Departamento de Imunologia, Instituto de Ciencias Biomedicas, Universidade de São Paulo, São Paulo 05508-000, Brazil
2 shared publications - Marília Oliveira Fonseca Goulart
Federal University of Alagoas
2 shared publications - John Marques Dos Santos
Instituto de Química e Biotecnologia (IQB), Universidade Federal de Alagoas (UFAL), Campus A. C. Simões, Tabuleiro dos Martins, 57072-970 Maceió, AL, Brazil
1 shared publication - Orlando Roberto Pimentel Araújo
Instituto de Química e Biotecnologia (IQB), Universidade Federal de Alagoas (UFAL), Brazil
1 shared publication - Orlando Roberto Pimentel de Araújo
Institute of Chemistry and Biotechnology, Federal University of Alagoas, Maceio 57072-970, Brazil
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 18 December 2015
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 16 (12) , 30269-30308
Oxidative Stress and Inflammation in Hepatic Diseases: Therapeutic Possibilities of N-Acetylcysteine
Liver disease is highly prevalent in the world. Oxidative stress (OS) and inflammation are the most important pathogenetic events in liver diseases, regardless the different etiology and natural course. N-acetyl-l-cysteine (the active form) (NAC) is being studied in diseases characterized by increased OS or decreased glutathione (GSH) level. NAC acts mainly on the supply of cysteine for GSH synthesis. The objective of this review is to examine experimental and clinical studies that evaluate the antioxidant and anti-inflammatory roles of NAC in attenuating markers of inflammation and OS in hepatic damage. The results related to the supplementation of NAC in any form of administration and type of study are satisfactory in 85.5% (n = 59) of the cases evaluated (n = 69, 100%). Within this percentage, the dosage of NAC utilized in studies in vivo varied from 0.204 up to 2 g/kg/day. A standard experimental design of protection and treatment as well as the choice of the route of administration, with a broader evaluation of OS and inflammation markers in the serum or other biological matrixes, in animal models, are necessary. Clinical studies are urgently required, to have a clear view, so that, the professionals can be sure about the effectiveness and safety of NAC prescription.
- 18 December 2015
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 16 (12) , 30269-30308
Top Cited PapersOpen AccessOxidative Stress and Inflammation in Hepatic Diseases: Therapeutic Possibilities of N-Acetylcysteine
Liver disease is highly prevalent in the world. Oxidative stress (OS) and inflammation are the most important pathogenetic events in liver diseases, regardless the different etiology and natural course. N-acetyl-l-cysteine (the active form) (NAC) is being studied in diseases characterized by increased OS or decreased glutathione (GSH) level. NAC acts mainly on the supply of cysteine for GSH synthesis. The objective of this review is to examine experimental and clinical studies that evaluate the antioxidant and anti-inflammatory roles of NAC in attenuating markers of inflammation and OS in hepatic damage. The results related to the supplementation of NAC in any form of administration and type of study are satisfactory in 85.5% (n = 59) of the cases evaluated (n = 69, 100%). Within this percentage, the dosage of NAC utilized in studies in vivo varied from 0.204 up to 2 g/kg/day. A standard experimental design of protection and treatment as well as the choice of the route of administration, with a broader evaluation of OS and inflammation markers in the serum or other biological matrixes, in animal models, are necessary. Clinical studies are urgently required, to have a clear view, so that, the professionals can be sure about the effectiveness and safety of NAC prescription.
- Open Access
- 1 December 2015
- Published by Elsevier in Redox Biology
- Vol. 6, 617-639
Antioxidant therapy for treatment of inflammatory bowel disease: Does it work?
- 1 December 2015
- Published by Elsevier in Redox Biology
- Vol. 6, 617-639
Open AccessAntioxidant therapy for treatment of inflammatory bowel disease: Does it work?